Citalopram for the prevention of depression and its consequences in HIV-hepatitis c coinfected individuals initiating pegylated interferon/Ribavirin therapy: A multicenter Randomized double-blind placebo-controlled trial

HIV Clinical Trials

Volumn 15, Issue 4, 2014, Pages 161-175

  Klein, Marina ^a,b   Lee, Terry ^b   Brouillette, Marie Josée ^a,c,d   Sheehan, Nancy ^a,e   Walmsley, Sharon ^b,f   Wong, David ^f   Conway, Brian ^g   Hull, Mark ^h   Cooper, Curtis ^b,i   Haidar, Shariq ^j   Vezina, Sylvie ^k,l   Annable, Lawrence ^c   Young, Simon ^c,d   Zubyk, Wendy ^b   Singer, Joel ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Canadian HIV Trials Network   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

^h BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

ⁱ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^j MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^k Clinique Medicale l'Actuel   (Canada)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

citalopram; coinfection; depression; hepatitis C virus; HIV; interferon alpha

Indexed keywords

CITALOPRAM; CLONAZEPAM; PEGINTERFERON ALPHA2B; PLACEBO; PMS CITALOPRAM HYDROBROMIDE; REBETRON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BECK DEPRESSION INVENTORY; CANADIAN; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIXED INFECTION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

CITALOPRAM; COINFECTION; DEPRESSION; HEPATITIS C VIRUS; HIV; INTERFERON-ALPHA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIVIRAL AGENTS; CITALOPRAM; COINFECTION; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84906705021     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1504-161     Document Type: Article

References (39)

1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodefi ciency virus infection. Clin Infect Dis. 2001;32(3):492-497.
2. Campos NG, Salomon JA, Servoss JC, et al. Costeffectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007;120(3): 272-279.
3. Grishchenko M, Grieve RD, Sweeting MJ, et al. Costeffectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care. 2009;25(2):171-180.
4. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodefi ciency virus and hepatitis C virus. Hepatology. 2009;50(2):407-413.
5. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012;55(5):728-736.
6. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16(5):352-358.
7. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodefi ciency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis. 2003;36(1):97-100.
8. Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodefi ciency virus infection. Clin Infect Dis. 2003;36(8):1039-1046.
9. Taylor LE, Costello T, Alt E, Yates G, Tashima K. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS. 2002;16(12):1700-1701.
10. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord. 2004;82(2):175-190.
11. Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: A review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(4): 731-746.
12. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: Author; 2013.
13. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6): 580-593.
14. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl 1): S237-244.
15. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29(7):1051-1055.
16. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136-139.
17. Loftis JM, Hauser P. Safety of the treatment of interferon-alpha-induced depression. Psychosomatics. 2003;44(6):524-526.
18. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
19. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103(1-3):83-90.
20. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1163-1174.
21. Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: A 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(4):522-528.
22. Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: A randomized trial. Ann Intern Med. 2012;157(2):94-103.
23. Klein MB, Cooper C, Brouillette MJ, et al. CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials. 2008;29(4):617-30.
24. PEGETRON (ribavirin + peginterferon alfa-2b) [product monograph]. Merck & Co, Inc. December 17, 2012.
25. Gheorghe L, Iacob S, Sporea I, et al. Effi cacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointest Liver Dis. 2007;16(1):23-29.
26. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2):443-451.
27. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology.2002;123(4):1061-1069.
28. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(Suppl 2):S143-151.
29. Beck A, Steer R, Brown G. BDI-II Manual. 2nd ed. New York: Psychological Corporation; 1996.
30. Demyttenaere K, De Fruyt J. Getting what you ask for: On the selectivity of depression rating scales. Psychother Psychosom. 2003;72(2):61-70.
31. Castellon SA, Hinkin CH, Wood S, Yarema KT. Apathy, depression, and cognitive performance in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1998;10(3): 320-329.
32. Ferrando SJ, Rabkin JG, de Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry. 1999;60(11):741-746.
33. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44(2): 104-112.
34. Widiger T. DSM-IV Sourcebook. Arlington, VA: American Psychiatric Association; 1994.
35. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
36. Udina M, Castellvi P, Moreno-Espana J, et al. Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis. J Clin Psychiatry. 2012;73(8):1128-1138.
37. Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: Estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol. 2005;61(7):835-854.
38. Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. J Hepatol. 2012;57(6): 1379-1390.
39. Hou X-J, Xu J-H, Wang J, Yu Y-Y. Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: Metaanalysis of randomized, double-blind, placebo-controlled trials ? PLoS One. 2013;8(10):e76799.